FDA Approved: ALYFTREK — Original Application (Vertex Pharmaceuticals Incorporated)

View source ↗

Summary

The FDA approves ALYFTREK, a triple combination therapy of vanzacaftor, tezacaftor, and deutivacaftor, in an original application for cystic fibrosis. This repr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ALYFTREK (VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR)

Snippet

ORIG AP for ALYFTREK (VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR)